Discover and read the best of Twitter Threads about #bavencio
Most recents (3)
$PVCT Releases 2023 Stockholder Letter globenewswire.com/news-release/2… #rosebengal #rosebengalsodium
1/ $PVCT 2023 Shareholder Letter: (2) Design, prepare, and potentially commence a Phase 2/3 RCT of PV-10®+SOC checkpoint vs monotherapy SOC checkpoint ($MRK #keytruda, $BMY #opdivo) for 1st-line Stage III cutaneous melanoma. #rosebengal #rosebengalsodium. A THREAD.
2/ Utilizing clinical data from an ongoing, multi-cohort, Phase 1b/2 study of PV-10+checkpoint ($MRK #keytruda) for checkpoint-naïve metastatic melanoma (NCT02557321). #rosebengal #rosebengalsodium.
$LOAC - SPAC for 4D Pharma (#DDDD) due diligence thread including:
✅Company overview
✅Product overview
✅Collaborations with major #pharma companies ( $MRK, $PFE, and Merck KGaA)
✅Key competitors
✅Pipeline and upcoming catalysts
✅Company overview
✅Product overview
✅Collaborations with major #pharma companies ( $MRK, $PFE, and Merck KGaA)
✅Key competitors
✅Pipeline and upcoming catalysts
𝘾𝙤𝙢𝙥𝙖𝙣𝙮 𝙤𝙫𝙚𝙧𝙫𝙞𝙚𝙬
4D Pharma (#DDDD) is a pharmaceutical company leading the development of a novel class of drugs derived from the microbiome (LBPs).🦠
Here is a quick overview of how 4D utilizes the microbiome for unique solutions. vimeo.com/249654919
4D Pharma (#DDDD) is a pharmaceutical company leading the development of a novel class of drugs derived from the microbiome (LBPs).🦠
Here is a quick overview of how 4D utilizes the microbiome for unique solutions. vimeo.com/249654919
#DDDD / $LOAC is leading the microbiome sector with:
✅More than 1,000 granted patents
✅Partnerships with several large biopharma companies (Merck, Pfizer, Merck KGaA) and in talks with others
✅Unique discovery platform of live biotherapeutic products (LBPs)
✅More than 1,000 granted patents
✅Partnerships with several large biopharma companies (Merck, Pfizer, Merck KGaA) and in talks with others
✅Unique discovery platform of live biotherapeutic products (LBPs)
1. My great thanks to @sandrapdangelo & @WTapMD for elaborating on the $250,000 grant they got from @CureSarcoma for uterine #leiomyosarcoma. curesarcoma.org/uterine-leiomy… Their research will help people with other #sarcoma subtypes, too. more ...
2. @sandrapdangelo says grant will go toward 2 immunotherapy #ClinicalTrials. She hopes the first will open @sloan_kettering in late spring. The first will combine a CSF-1R (DCC-3014 deciphera.com/pipeline/dcc-3…) with #avelumab (#Bavencio en.wikipedia.org/wiki/Avelumab). more ...
3. @sandrapdangelo doesn't know when the second #ClinicalTrial will open, but it will combine a PARP inhibitor (en.wikipedia.org/wiki/PARP_inhi…) an immunotherapy drug that has not been chosen yet. "Other #sarcoma subtypes will be allowed to enroll," not just #leiomyosarcoma. more ...
